Aptose Biosciences Inc. (NASDAQ: APTO) share were dipping -25.65% to 4.55 in the premarket trading after the company released highlights from a business update, In conjunction with attendance at the 2020 Annual Meeting of the American Society of Hematology (ASH) event held on Sunday, December 6th,
The current clinical status of CG-806, Aptose oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor has been evaluated by the Aptose management team in two phases 1 a/b trial, one in patients with refractory acute myeloid leukemia (AML) and the other in patients with relapsed or refractory B-cell malignancies. The committee has also evaluated the clinical status of acute myeloid leukemia (AML) (MDS).
